Scarica l'app Stockscreener
77.56
0.10%
0.08
Dopo l'orario di chiusura:
78.62
1.06
+1.37%
Precedente Chiudi:
$77.48
Aprire:
$75.93
Volume 24 ore:
896.95K
Relative Volume:
1.42
Capitalizzazione di mercato:
$3.46B
Reddito:
$156.12M
Utile/perdita netta:
$-395.33M
Rapporto P/E:
-7.4751
EPS:
-10.3758
Flusso di cassa netto:
$-292.33M
1 W Prestazione:
-3.80%
1M Prestazione:
+3.63%
6M Prestazione:
+59.36%
1 anno Prestazione:
+118.97%
Intervallo 1D:
$75.09
$79.00
Intervallo di 1 settimana:
$75.09
$81.71
Portata 52W:
$35.43
$118.84
Grail Inc Stock (GRAL) Company Profile
Nome
Grail Inc
Settore
Industria
Telefono
(833) 694-2553
Indirizzo
1525 O'BRIEN DRIVE, MENLO PARK
Compare GRAL vs TMO, DHR, NTRA, IQV, A
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
GRAL
Grail Inc
|
77.56 | 3.46B | 156.12M | -395.33M | -292.33M | -10.38 |
TMO
Thermo Fisher Scientific Inc
|
603.18 | 223.95B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
200.53 | 144.01B | 24.78B | 3.68B | 5.29B | 5.1743 |
NTRA
Natera Inc
|
326.14 | 47.61B | 2.50B | -226.32M | 71.51M | -1.6412 |
IQV
Iqvia Holdings Inc
|
257.30 | 42.30B | 16.63B | 1.39B | 2.12B | 8.0674 |
A
Agilent Technologies Inc
|
143.12 | 40.81B | 7.23B | 1.41B | 1.09B | 4.979 |
Grail Inc Stock (GRAL) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-10 | Iniziato | Mizuho | Neutral |
| 2026-03-18 | Aggiornamento | TD Cowen | Hold → Buy |
| 2026-02-19 | Iniziato | TD Cowen | Hold |
| 2026-02-17 | Iniziato | Robert W. Baird | Outperform |
| 2025-12-02 | Ripresa | Morgan Stanley | Equal-Weight |
| 2025-11-12 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2025-04-21 | Iniziato | Canaccord Genuity | Buy |
| 2024-11-27 | Iniziato | Morgan Stanley | Equal-Weight |
| 2024-11-15 | Iniziato | Wolfe Research | Peer Perform |
| 2024-10-17 | Iniziato | Guggenheim | Neutral |
Mostra tutto
Grail Inc Borsa (GRAL) Ultime notizie
Analysts Offer Insights on NA Companies: Chime Financial, Inc. Class A (CHYM), GRAIL Inc (GRAL) and ServiceTitan, Inc. Class A (TTAN) - The Globe and Mail
UBS Initiates Coverage of Grail With Buy Rating, Caris, Tempus, Twist With Neutral - genomeweb.com
Why Is GRAL Stock Down Today? Analysts Lower Targets After UK Trial Setback But Call Selloff Overdone - Stocktwits
Grail CFO Sells 7,900 Shares Amid Strong Stock Performance - Intellectia AI
Grail CFO Aaron Freidin Sells 7,900 Shares for $672,000 - Yahoo Finance
GRAL INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announc - The National Law Review
Grail Stock Jumps in August as FDA Schedules a Key Meeting for its Galleri Cancer Test - Yahoo Finance
GRAIL Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - Moomoo
Have Insiders Sold GRAIL Shares Recently? - simplywall.st
GRAIL grants 55,867 RSUs to 59 new employees as hiring incentive under Nasdaq rules. - Pluang
GRAIL (GRAL) Institutional Ownership 2026 $GRAL - MarketBeat
Grail CFO Aaron Freidin sells $671,579 in company stock By Investing.com - Investing.com South Africa
Grail CFO Aaron Freidin sells $671,579 in company stock - Investing.com
Grail CEO Joshua Ofman sells $425,098 in company stock - Investing.com
GRAIL CFO sells 7,900 shares at $85.01 avg - Stock Titan
GRAIL to Present at Morgan Stanley's 24th Annual Global Healthcare Conference - TradingView
GRAIL (NASDAQ: GRAL) insider Joshua Ofman plans to sell 10,000 shares - Stock Titan
Biotech Frenzy Sends GRAIL Soaring Ahead of FDA Showdown - TipRanks
Investigation announced for Long-Term Investors in shares of GRAIL, Inc. (NASDAQ: GRAL) over potential Wrongdoing - openPR.com
GRAIL (GRAL) Earnings Report: Profit Per Share Surpasses Its Benchmark in the Current Update; Post-Report: The Market Price Advances 6.19% in Latest TradingGross Profit Margin - dars.gov.et
Grail Stock Rockets Back As Traders Buy The Dip - TipRanks
GRAIL (GRAL), What Is Behind The Fresh Attention On The Stock? - simplywall.st
Why Silver Grail Resources Ltd stock is skyrocketing today - Wealth Awesome
Whoop expands Advanced Labs to non-members, adds Grail’s multi-cancer detection test to lineup - Fierce Healthcare
Russell Investments Group Ltd. Has $1.94 Million Holdings in GRAIL, Inc. $GRAL - MarketBeat
How (GRAL) Movements Inform Risk Allocation Models - news.stocktradersdaily.com
GRAL Q2 2026 Earnings: Narrower-Than-Expected Loss Highlights Cost DisciplineEarnings Season Review - Vinanet
GRAIL Highlights Galleri Growth Ahead of Key FDA Advisory Meeting - MarketBeat
GRAL|Grail Inc|Price:68.180|Chg%:-0.760 - TradingKey
Farallon group discloses 9.6% GRAIL, Inc. (GRAL) holding in Schedule 13G/A - Stock Titan
GRAIL Q2 2026 Earnings: EPS Beats Estimates by 5.37% Amid Muted Stock ReactionEarnings Acceleration Picks - Vinanet
GRAIL Inc. (GRAL) Edges Lower 0.84% as Shares Hold Above $64.94 SupportValue Area Low - Vinanet
GRAIL2026 Funding Rounds & List of Investors - Tracxn
GRAIL, Inc. (NASDAQ:GRAL) Given Consensus Recommendation of "Hold" by Brokerages - MarketBeat
Bank of America Corp DE Purchases 205,611 Shares of GRAIL, Inc. $GRAL - MarketBeat
GRAIL: Looking Beyond The NHS-Galleri Headline (NASDAQ:GRAL) - Seeking Alpha
GRAIL (NASDAQ:GRAL) Stock Price Down 6.3%What's Next? - MarketBeat
Cancer Detection Firm Nears FDA Breakthrough Blood-Test Review - Streetwise Reports
GRAIL Galleri Test Heads to FDA Panel for Multi-Cancer Screening Review - Streetwise Reports
GRAIL INC : PIPER SANDLER RAISES TARGET PRICE TO $74 FROM $56 - webull.com
FDA panel to review GRAIL’s Galleri multi-cancer blood test in September - Mugglehead Investment Magazine
GRAIL (NASDAQ:GRAL) Trading Up 7.6%Time to Buy? - marketbeat.com
FDA Panel Schedules to Evaluate GRAIL Premarket Approval Application for Multi-Cancer Early Detection Test - Benzinga
FDA panel to weigh Grail’s Galleri test - STAT
GRAIL’s Galleri becomes first multi-cancer detection test headed to US FDA advisory panel - AllSci
Renaissance Technologies LLC Sells 30,100 Shares of GRAIL, Inc. $GRAL - MarketBeat
Illumina Seeks Court Approval of GRAIL Settlement - The Globe and Mail
GRAIL Inc Revenue Breakdown – LSX:A40F8M - TradingView
Is GRAIL (GRAL) Fairly Valued Following Galleri Adoption Growth And The FDA Panel Date? - Yahoo Finance
US FDA to hold advisory meeting to review Grail’s multi-cancer test - WTVB
US FDA to hold advisory meeting to review Grail's multi-cancer test - Reuters
Grail Inc Azioni (GRAL) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.83%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):